Avid Biosciences
Avid Bioservices' expansion will double existing capacity to service both a $40m backlog and its owner Peregrine.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $1.1b Valuation: $1.1b 7.9x EV/Revenue -95.8x EV/EBITDA | Buyout | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (7 %) | - | 11 % | 61 % | 25 % | 25 % | (6 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (31 %) | (5 %) | (17 %) | 13 % | 13 % | 3 % | (8 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (41 %) | (8 %) | (18 %) | 12 % | 107 % | - | (101 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Avid Biosciences, originally a subsidiary of Peregrine Pharmaceuticals, was founded in 2002 by Edward Legere. The company was established as a contract development and manufacturing organization (CDMO) with a focus on biologics. This strategic move allowed Avid to carve out a niche in the pharmaceutical industry, providing essential services in drug substance development and manufacturing.
Over the years, Avid Biosciences grew steadily, leveraging its expertise to support a wide range of clients in the biotech and pharmaceutical sectors. The company's commitment to quality and innovation helped it build a strong reputation as a reliable partner in the development of complex biologics.
A significant milestone in Avid's journey occurred in November 2024, when it was announced that the company would be acquired by GHO Capital Partners and Ampersand Capital Partners. This acquisition marked a new chapter for Avid, providing the company with additional resources and strategic support to expand its capabilities and reach in the global market.
Today, Avid Biosciences continues to thrive as a key player in the CDMO space, driven by a mission to advance the development and manufacturing of life-saving biologics. The company's journey from a subsidiary to an industry leader exemplifies the impact of strategic focus and dedication in the competitive world of biotechnology.